Announcement PDF ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 28 August 2026 Manager, Company Announcements ASX Limited Exchange Place Level 27, 39 Martin Place Sydney NSW 2000 Via E-Lodgement Dear Sir/Madam OncoSil Medical Limited Full Year Results – financial year ended 30 June 2026 Please find attached the following documents relating to the results for the year ended 30 June 2026: • Appendix 4E • Annual Report This announcement comprises the information required by ASX Listing Rule 4.3A. Yours faithfully, OncoSil Medical Limited Click here to view this announcement on Investor Hub. OncoSil Medical Ltd Appendix 4E Preliminary final report 1. Company details Name of entity: OncoSil Medical Ltd ABN: 89 113 824 141 Reporting period: For the year ended 30 June 2026 Previous period: For the year ended 30 June 2025 2. Results for announcement to the market $ Revenues from ordinary activities up 43.9% to 1,684,978 Other income and interest revenue up 678.2% to 3,543,737 Loss from ordinary activities after tax attributable to the owners of OncoSil Medical Ltd down 28.1% to (10,860,122) Loss for the year attributable to the owners of OncoSil Medical Ltd down 28.1% to (10,860,122) Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $10,860,122 (30 June 2025: $15,099,844). Refer to Market announcement, which precedes the Appendix 4E, and the 'Review of operations' section of the Directors' report for further commentary on the results for the year ended 30 June 2026. 3. Net tangible assets Reporting period Previous period Cents Cents Net tangible assets per ordinary security 16.18 21.86 Consolidated 2026 2025 Calculated as follows: $ $ Net assets 4,996,374 3,103,521 Less: Right-of-use assets (13,298) (65,331) Add: Lease liabilities 14,782 69,915 Net tangible assets 4,997,858 3,108,105 Number of shares 2026 2025 Number of shares on issue at 30 June 30,888,898Syntax Warning: Bad annotation destination 14,220,777 OncoSil Medical Ltd Appendix 4E Preliminary final report 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividend reinvestment plans Not applicable. 7. Details of associates and joint venture entities Not applicable. 8. Foreign entities Details of origin of accounting standards used in compiling the report: Not applicable. 9. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements have been audited and an unmodified opinion has been issued, which includes a paragraph addressing a material uncertainty related to going concern. 10. Attachments Details of attachments (if any): The Annual Report of OncoSil Medical Ltd for the year ended 30 June 2026 is attached. 11. Signed On behalf of the Directors. Signed ___________________________ Date: 28 August 2026 Dr Thomas Duthy Non-Executive Chairman Sydney OncoSil Medical Ltd ABN 89 113 824 141 Annual Report - 30 June 2026 OncoSil Medical Ltd Contents 30 June 2026 1 Corporate directory 2 Chairman's letter 3 CEO's report 6 Directors' report 9 Auditor's independence declaration 30 Statement of profit or loss and other comprehensive income 31 Statement of financial position 32 Statement of changes in equity 33 Statement of cash flows 34 Notes to the financial statements 35 Consolidated entity disclosure statement 65 Directors' declaration 66 Independent auditor's report to the members of OncoSil Medical Ltd 67 Shareholder information 72 OncoSil Medical Ltd Corporate directory 30 June 2026 2 Directors Dr Thomas Duthy - Chairman Mr Nigel Lange Ms Lel Smits Joint company secretary Tim Luscombe Nova Taylor Notice of annual general meeting The details of the annual general meeting of OncoSil Medical Ltd are: 11:00 (AEDT) Wednesday 18 November 2026 The meeting will be held virtually. Registered office and principal place of business Level 5 7 Eden Park Drive Macquarie Park, NSW 2113 Phone: +61 2 8935 9629 Share register Automic Pty Ltd Level 5 126 Phillip Street Sydney NSW 2000 Phone: +61 2 9698 5414 Auditor Crowe Sydney Level 24 1 O'Connell Street Sydney NSW 2000 Solicitors K&L Gates Level 25, South Tower 525 Collins Street Melbourne VIC 3000 Bankers National Australia Bank 330 Collins Street Melbourne VIC 3000 Stock exchange listing OncoSil Medical Ltd shares are listed on the Australian Securities Exchange (ASX code: OSL) Website www.oncosil.com Corporate Governance Statement OncoSil Medical Ltd and the Board of Directors are committed to achieving and demonstrating the highest standards of corporate governance. OncoSil Medical Ltd has reviewed its corporate governance practices against the Corporate Governance Principles and Recommendations (4th Edition) published by the ASX Corporate Governance Council. Details of the corporate governance report is available on the Group website at: https://investors.oncosil.com/corporate-governance OncoSil Medical Ltd Chairman's letter 30 June 2026 3 Dear Shareholders, On behalf of the Board of Directors, I am pleased to present OncoSil Medical Limited's Annual Report for the financial year ended 30 June 2026. This has been a transformative year for OncoSil Medical. During the year, we achieved several significant regulatory, clinical and commercial milestones that further advanced our mission of improving outcomes for patients suffering from one of the most challenging forms of cancer. These achievements reflect the dedication of our employees, clinical investigators, commercial partners and shareholders, all of whom have contributed to the Company's continued progress. A landmark regulatory year The single most significant event of FY26 was the approval by Australia's Therapeutic Goods Administration (TGA) of the OncoSil™ device in May 2026. This approval enables inclusion on the Australian Register of Therapeutic Goods for the treatment of unresectable locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. This approval opens our home market for the first time, and with approximately 4,350 new cases of pancreatic cancer diagnosed in Australia each year, the clinical need is both clear and immediate. We anticipate launching in Australia in the first half of the 2027 calendar year. Approval from the Therapeutic Goods Administration (TGA) also validates the quality of our manufacturing operations at our Macquarie Park, New South Wales facility. As we scale production to meet anticipated domestic and export demand, this facility will serve as the backbone of our global supply chain. In Europe, our regulatory position continues to strengthen. The Medical Device Regulation (MDR) certification achieved in January 2025 has already materially simplified commercial treatment initiation across the European Union and United Kingdom, a benefit that flowed directly into our strongest ever sales performance in FY26. We are also progressing regulatory submissions to extend our CE Mark to include use with FOLFIRINOX chemotherapy and percutaneous delivery via Interventional Radiology, both of which are anticipated in the second half of calendar year 2026. In the United States, we were very pleased to announce in June 2026 the US Food and Drug Administration (FDA) confirming that all outstanding questions relating to the Company's Humanitarian Device Exemption (HDE) application for the treatment of distal cholangiocarcinoma (dCCA) had been satisfactorily addressed. We submitted our HDE package in early July and on 17 August 2026 were very pleased to receive FDA HDE approval for the OncoSil™ device in dCCA. This is a major milestone in the Company’s history with very few ASX listed medical device companies having achieved an FDA approval for a Class III medical device like ours. Clinical momentum converting to commercial outcomes The clinical de-risking of OncoSil™ device has been a multi-year endeavour, and FY26 has seen that investment bear significant fruit. Firstly, the PANCOSIL study, which was an investigator-initiated Phase 1/2 feasibility trial led by Amsterdam UMC. On 18 September 2025 we announced PANCOSIL delivered strong technical feasibility and encouraging preliminary efficacy results. Data was presented at the CIRSE 2025 Congress in Barcelona. As the first study in the world to administer the OncoSil™ device by CT-guided percutaneous injection, PANCOSIL demonstrated that this less invasive delivery approach is both safe and feasible. We are targeting a regulatory submission in the second half of the 2026 calendar year to support percutaneous administration as an approved delivery method, which opens up an entire new clinical speciality group highly familiar with technologies like the OncoSil™ device, namely the interventional radiologists. In June, we announced the results of the TRIPP-FFX study. The study met both of its co-primary endpoints. While the study was designed as a non-comparative trial and was not powered for direct statistical comparison between treatment arms, these outcomes represent an important addition to the growing body of clinical evidence supporting the OncoSil™ device in a disease of profound unmet need. Together with the completion of the investigator-initiated PANCOSIL study, this milestone allows the Board to turn its focus firmly toward regulatory engagement and commercial execution, and the Company is preparing a regulatory submission intended to extend the device's CE Mark to include use in combination with FOLFIRINOX. OncoSil Medical Ltd Chairman's letter 30 June 2026 4 Separately, a comparative study presented at Digestive Disease Week 2025 by investigators from the Royal Adelaide Hospital demonstrated superior outcomes for patients treated with OncoSil™ over stereotactic body radiation therapy, with median overall survival of 22 months versus 14 months. This data, which is generated independently by leading clinicians is invaluable in building physician confidence and institutional adoption. On behalf of the Board, I extend my sincere thanks to the patients, clinicians and investigators whose participation made this progress possible. Germany: The pivotal market Germany remains our most strategically significant near-term commercial opportunity. The G-BA (Gemeinsamer Bundesausschuss) sponsored study, commencing in the second half of calendar year 2026, has the potential to unlock access to Germany's entire public hospital reimbursement system consisting of a market with approximately 20,000 new pancreatic cancer cases per year and one of Europe's most structured and well-funded healthcare environments. The addressable market opportunity in Germany is conservatively in the order 2.000 to 3.000 patients annually. Commercial momentum in Germany has continued to build. The number of hospitals eligible to seek NUB (Neue Untersuchungs- und Behandlungsmethoden) reimbursement for the OncoSil™ device has grown substantially, and the first successful treatment at Vivantes Neukölln Hospital in Berlin represents one of the largest hospitals in Germany's largest municipal hospital network. This is an important first step in embedding the OncoSil™ device within leading German oncology centres. We regard the G-BA trial as a potential inflection point not only for Germany but for reimbursement negotiations across other European member states that frequently reference G- BA decisions. Capital management and financial discipline In February 2026, we completed an $8 million capital raise comprising a $6 million placement and a $2.0 million fully underwritten non-renounceable entitlement offer, supported by new and existing substantial shareholders including Pengana Capital Group and Regal Funds Management as cornerstone investors. Your Directors also participated in this raise with a commitment of $0.11 million. A further $1.84 million R&D tax incentive refund was received in the second half of the year. CEO Nigel Lange's decision to convert a 10% salary reduction into ordinary shares reflects a commitment shared across our leadership team: to align management incentives directly with shareholder value creation at this critical stage of the Company's commercialisation journey. We continue to manage the cost base with discipline. Annualised cost savings of $3.4 million to $3.9 million have been identified for realisation from FY27, ensuring that as revenues grow, the operating leverage in our business model translates into meaningful shareholder returns. Board and governance During FY26 the Board was refreshed to align its composition with the Company's next phase of clinical and commercial execution. I joined the Board as a Non-Executive Director on 11 July 2025 and was subsequently appointed Non-Executive Chairman following Mr Douglas Cubbin's retirement. As a demonstration of my confidence in OncoSil Medical and my alignment with the interests of shareholders, I elected to sacrifice 100% of my Non-Executive Director fees in favour of equity, taken as OncoSil Medical shares at $1.50 per share; an approach also adopted by my fellow Non-Executive Director Lel Smits. On behalf of the Board, I extend my sincere thanks to the Directors who stepped down during the year, namely Dr Gabriel Liberatore, who departed in July 2025, and Mr Douglas Cubbin, who retired as Chairman and Non-Executive Director in November 2025, for their counsel, commitment and valued contribution to the Company, and we wish them well. The Board continues to review its composition and governance practices against the ASX Corporate Governance Council's Principles and Recommendations (4th Edition), details of which are available on our investor relations page at https://investors.oncosil.com/corporate-governance. Pancreatic cancer carries a prognosis that is, for most patients, measured in months. The OncoSil™ device offers the possibility of more time and more months with family, more time to fight, and in some cases, a pathway to surgical resection that was previously unavailable. That clinical reality is the foundation of our commercial opportunity and the enduring motivation for every member of our team. OncoSil Medical Ltd Chairman's letter 30 June 2026 5 On behalf of the Board, I thank our shareholders, our clinical partners, our distribution network, and our dedicated staff for their continued commitment. I also thank our patients, and those who love them, for the trust they place in our technology and in the clinicians who deliver it. We look forward to reporting further progress. ___________________ Dr Thomas Duthy Non-Executive Chairman OncoSil Medical OncoSil Medical Ltd CEO's report 30 June 2026 6 Dear Shareholders, FY26 was a defining year for OncoSil Medical. It marked the transition of our business from one primarily focused on building clinical and regulatory foundations to one increasingly demonstrating commercial execution, a growing body of clinical evidence and global market readiness. Over the past twelve months, we have delivered meaningful progress across every pillar of our strategy. Commercial adoption accelerated, clinical evidence reached important inflection points, regulatory momentum continued to strengthen, and our clinical data received increasing international recognition. Together, these achievements reinforce our belief that OncoSil™ is evolving into a globally recognised treatment option for patients with unresectable locally advanced pancreatic cancer while creating a platform for sustainable long-term shareholder value. Importantly, FY26 demonstrated that our strategy is viable. The investments we have made over recent years in clinical development, regulatory approvals, physician education and market access are now translating into measurable commercial outcomes. Unit sales increased by 53% and revenue grew by 44% compared with FY25, reflecting growing physician acceptance, resulting in increased utilisation across our commercial markets. Building evidence that changes clinical practice Our long-term success is dependent on establishing OncoSil™ as an accepted therapy option in routine pancreatic cancer treatment. During FY26 we made significant progress toward that objective. The positive results from the TRIPP-FFX study represent one of the most important milestones in the Company's history. Successfully achieving both co-primary endpoints demonstrated that OncoSil™, in addition to FOLFIRINOX chemotherapy, delivers encouraging clinical outcomes while maintaining an acceptable safety profile. These results provide a clear pathway toward expanding our product label to align with today's standard- of-care treatment regimen and have the potential to significantly increase the addressable patient population in Europe. Equally important was the international recognition these data received from a presentation conducted at ESMO GI 2026. Selection for a Rapid Oral Presentation at one of the world's leading gastrointestinal oncology congresses acknowledges both the quality and significance of our clinical program while increasing awareness among the global gastrointestinal oncology community. Alongside TRIPP-FFX, the OSPREY Registry continued to generate compelling real-world evidence, with data presented at ESGE (European Society of Gastroenterology) and ASCO (American Society of Clinical Oncology) further corroborating the safety, efficacy and clinical utility of OncoSil™ in routine practice. Combined with new peer-reviewed publications confirming the device's highly localised mechanism of action, these independent datasets continue to strengthen confidence and support broader commercial adoption. During FY26, we also completed the PANCOSIL investigator-initiated study, which evaluates CT-guided percutaneous delivery of OncoSil™ as an alternative to endoscopic implantation. The presentation of the results at CIRSE 2025 (Cardiovascular and Interventional Radiological Society of Europe) provided important international exposure within the interventional radiology/interventional oncology community and highlighted the strategic potential of this delivery pathway. Subject to regulatory approval and label expansion, percutaneous administration serves to broaden access to interventional radiologists, enable treatment in additional clinical settings, reduce procedural barriers and significantly expand the addressable market for OncoSil™. Collectively, these achievements strengthen our competitive position and move us closer to establishing OncoSil™ as a recognised standard treatment option for patients with unresectable locally advanced pancreatic cancer. Expanding global market opportunities FY26 also represented a year of substantial regulatory progress. Advancing our U.S. Humanitarian Device Exemption (HDE) application to the final stage of FDA review during the financial year brings us closer than ever to entering the United States market. We secured the FDA HDE on 17 August 2026, which represented the culmination of our significant internal efforts and generation of the necessary clinical evidence to support the approval process. While our initial indication focuses on distal cholangiocarcinoma (dCCA), this successful approval represents one of the single most important strategic milestones of our regulatory platform and provides market access to the world's largest healthcare market. We anticipate a commercial launch in the first half of the 2027 calendar year. OncoSil Medical Ltd CEO's report 30 June 2026 7 Domestically, receiving Therapeutic Goods Administration (TGA) approval in our home market allows us to commence commercialisation in Australia in the first half of calendar year 2027, adding another important market to our global expansion strategy while strengthening manufacturing, clinical collaboration and physician engagement closer to home. In Europe, continued progress with reimbursement, procurement pathways and ethics approvals -particularly in Italy - further reduces barriers to adoption and simplifies commercial implementation across existing markets. Rather than isolated regulatory achievements, these milestones represent coordinated steps in building a diversified global commercial business supported by multiple revenue opportunities. Executing on commercial growth As a medical technology company, long-term value is created not simply through innovation but through successful commercial execution. Our commercial growth during FY26 reflects increasing utilisation by existing treatment centres, continued expansion into new centres and growing physician confidence supported by a stronger body of clinical evidence. Germany remains the most central and important market for OncoSil™ in Europe, reflecting the country's large addressable patient population, well-established healthcare infrastructure, and strong network of specialist treatment centres. As the cornerstone of the Company's European commercial strategy, Germany presents a significant opportunity to expand adoption of OncoSil™ while advancing the G-BA clinical study. This strategically important study is expected to generate robust clinical and real-world evidence to further demonstrate the therapy's clinical and economic value, supporting reimbursement, strengthening physician confidence, and reinforcing OncoSil™ Medical’s long-term commercial position in Germany and across Europe. Importantly, commercial momentum is becoming increasingly self-reinforcing. As more physicians gain experience with OncoSil™, more clinical data become available, more publications are produced and broader reimbursement pathways are established, adoption becomes progressively easier across new markets. This creates a scalable commercial model where scientific validation and commercial execution work together to accelerate growth. Strengthening our financial foundation FY26 also reflected continued financial discipline as we balanced investment in growth with careful management of our cost base. The Company ended the year with $6.5 million in cash and cash equivalents, strengthened by an $8 million capital raise completed during the year. Customer receipts grew 179% year-on-year to $2.1 million, reflecting the same commercial momentum driving our unit sales and revenue growth. We continued to invest meaningfully in research and development during FY26, directing $3.8 million toward our clinical program, including the TRIPP-FFX and PANCOSIL studies that delivered the milestone results described above. As these trials have since moved into their close-out phase, we expect R&D cash outflows to begin declining from the second quarter of FY27. Alongside this investment, we have taken deliberate steps to sharpen our cost base, targeting annualised cost savings of $3.4 million to $3.9 million from FY27 as we transition toward a more scalable commercial model. Combined with the anticipated completion of our new Macquarie Park manufacturing facility in Sydney, expected to improve gross margins and reduce cost of goods sold, we believe FY27 represents an important inflection point where clinical, regulatory and commercial investment increasingly translates into operating leverage. Accelerating commercial growth in FY27 While FY26 delivered significant achievements, we believe the opportunities ahead are even more compelling. Our focus during FY27 will be on converting the strong foundations established over recent years into accelerated commercial growth. OncoSil Medical Ltd CEO's report 30 June 2026 8 Key priorities include: • Launching OncoSil™ in the United States, establishing the Company's first commercial presence in the world's largest healthcare market; • Advancing regulatory submissions and approvals to expand the OncoSil™ label to include FOLFIRINOX chemotherapy, aligning the therapy with the current standard-of-care treatment regimen and significantly increasing the eligible patient population; • Advancing regulatory submission and approvals for percutaneous delivery of OncoSil™, broadening access to interventional radiologists, enabling treatment in additional clinical settings and significantly expanding the addressable market. • Commencing the fully funded G-BA clinical trial in Germany, an important milestone necessary to support future reimbursement in Europe's largest pancreatic cancer market; • Commencing commercial rollout following Australian TGA approval; • Continuing to expand physician adoption across existing European markets; • Leveraging our growing body of clinical and real-world evidence to support reimbursement and market access initiatives; and • Completing our new manufacturing facility in Macquarie Park to strengthen production capacity, reduce cost of goods sold, improve gross margins, enhance supply chain resilience and support future global demand. Each of these milestones has the potential to further strengthen our competitive position while expanding our addressable market. A platform for sustainable growth Pancreatic cancer remains one of the most challenging cancers to treat, with limited therapeutic options available for patients diagnosed with locally advanced disease. At OncoSil Medical, our purpose remains clear: to improve patient outcomes through innovative, targeted therapies supported by robust clinical evidence. Today, we are in a stronger position than at any time in our history. We have an expanding commercial business, an increasingly differentiated clinical evidence base, multiple regulatory catalysts ahead and a growing international network of physicians advocating for our technology. While there remains important work ahead, FY26 has demonstrated that our strategy is delivering measurable results and positioning the Company for sustained long-term growth. On behalf of the Board and management team, I would like to sincerely thank our employees, investigators, clinical partners, distributors and shareholders for their continued commitment and support. Together, we are building a company capable of making a meaningful difference for patients while creating enduring value for our shareholders. ___________________ Mr Nigel Lange Chief Executive Officer & Managing Director OncoSil Medical OncoSil Medical Ltd Directors' report 30 June 2026 9 The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of OncoSil Medical Ltd (referred to hereafter as ('OncoSil Medical', 'the Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2026. Directors The following persons were directors of OncoSil Medical Ltd during the whole of the financial year and up to the date of this report, unless otherwise stated: Dr Thomas Duthy Non-Executive Director & Chairman (appointed on 11 July 2025 and on 1 October 2025, respectively) Mr Nigel Lange Chief Executive Officer and Managing Director Ms Lel Smits Non-Executive Director Mr Douglas Cubbin Non-Executive Chairman (resigned as Chairman on 1 October 2025 and as Non-Executive Director on 19 November 2025) Dr Gabriel Liberatore Non-Executive Director (resigned on 11 July 2025) Information on directors Name: Dr Thomas Duthy Title: Non-Executive Director & Chairman (appointed on 11 July 2025 and on 1 October 2025, respectively) Qualifications: Dr Duthy holds a PhD from the University of Adelaide and an MBA from Deakin University. Experience and expertise: Dr Duthy brings more than 22 years of experience across financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. Dr Duthy is the Founder and Director of Nemean Group, a corporate advisory firm serving healthcare and technology companies, and has been involved in numerous successful M&A transactions including the $100 million sale of Ellex Medical Lasers (ASX:ELX) equipment business to Lumibird in 2020, the $111 million takeover of Limeade (ASX:LME) by WebMD in 2023 and the takeover of Pivotal Systems (ASX:PVS) also in 2023. He was previously Head of Corporate Development and Investor Relations at Sirtex Medical (ASX:SRX), where he played a key role in its $1.9 billion acquisition by China Grand Pharma/CDH and is the largest medical device transaction in Australian history. Other current directorships: None Former directorships (last 3 years): Arovella Therapeutics (ASX:ALA), Neurotech International (ASX:NTI), Neurizon Therapeutics (ASX:NUZ), Invex Therapeutics (ASX:IXC) Special responsibilities: Member of the Nomination and Remuneration Committee and member of the Audit and Risk Committee Interests in shares: 50,537 ordinary shares (owned by related party) 41,067 escrow shares until 11 July 2026 (owned by related party) Interests in options: 50,537 listed options (owned by related party) 172,811 unlisted options (owned by related party) OncoSil Medical Ltd Directors' report 30 June 2026 10 Name: Mr Nigel Lange Title: Chief Executive Officer and Managing Director Qualifications: BA, B.Comm Experience and expertise: Nigel joined the Company in May 2020 as Europe, Middle East and Africa ('EMEA') President and brings with him over 40 years of experience in the medical devices industry. Since 2003, Nigel has held various leadership roles with Sirtex Medical, a global leader in brachytherapy treatment for liver cancer. From 2003, Nigel served as Chief Executive Officer of Sirtex's European business, responsible for establishing their brachytherapy device in over 300 centres across Europe and the Middle East. Since 2017, Nigel served as Group Chief Commercial Officer where he was responsible for all commercial aspects of the global business. During this time, Nigel has also held interim roles including Interim Group CEO and Interim CEO of Asia Pacific. Other current directorships: None Former directorships (last 3 y